[{"address1": "5980 Horton Street", "address2": "Suite 550", "city": "Emeryville", "state": "CA", "zip": "94608", "country": "United States", "phone": "(510) 925-2492", "website": "https://kyvernatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.", "fullTimeEmployees": 119, "companyOfficers": [{"maxAge": 1, "name": "Mr. Warner  Biddle", "age": 57, "title": "CEO & Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 1232292, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Walker", "age": 62, "title": "Chief Technology Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 591360, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Jones M.B.A.", "age": 36, "title": "Chief Financial Officer", "yearBorn": 1988, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tom  Van Blarcom Ph.D.", "title": "Senior VP & Head of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy  Rossin", "age": 47, "title": "Senior Vice President of Corporate Affairs & Communications and Investor Relations", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cara  Bauer Ph.D.", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Maziasz", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Naji H. Gehchan M.B.A., M.D.", "age": 42, "title": "Chief Medical & Development Officer", "yearBorn": 1982, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sham  Dholakia DPHIL, M.D.", "title": "Chief Product Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.57, "open": 3.6, "dayLow": 3.43, "dayHigh": 4.06, "regularMarketPreviousClose": 3.57, "regularMarketOpen": 3.6, "regularMarketDayLow": 3.43, "regularMarketDayHigh": 4.06, "payoutRatio": 0.0, "forwardPE": -1.0254453, "volume": 826134, "regularMarketVolume": 826134, "averageVolume": 445850, "averageVolume10days": 907650, "averageDailyVolume10Day": 907650, "bid": 2.87, "ask": 4.48, "bidSize": 2, "askSize": 2, "marketCap": 174172176, "fiftyTwoWeekLow": 1.78, "fiftyTwoWeekHigh": 11.4, "fiftyDayAverage": 2.7529, "twoHundredDayAverage": 3.46885, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -103029056, "profitMargins": 0.0, "floatShares": 22191595, "sharesOutstanding": 43218900, "sharesShort": 2098502, "sharesShortPriorMonth": 2579347, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.048600003, "heldPercentInsiders": 0.12037, "heldPercentInstitutions": 0.68486, "shortRatio": 4.51, "shortPercentOfFloat": 0.0846, "impliedSharesOutstanding": 43218900, "bookValue": 5.183, "priceToBook": 0.777542, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -145419008, "trailingEps": -3.24, "forwardEps": -3.93, "enterpriseToEbitda": 0.642, "52WeekChange": -0.59334004, "SandP52WeekChange": 0.1116153, "quoteType": "EQUITY", "currentPrice": 4.03, "targetHighPrice": 25.0, "targetLowPrice": 5.0, "targetMeanPrice": 17.2, "targetMedianPrice": 20.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 242648992, "totalCashPerShare": 5.614, "ebitda": -160551008, "totalDebt": 6938000, "quickRatio": 7.289, "currentRatio": 7.439, "debtToEquity": 3.097, "returnOnAssets": -0.31076, "returnOnEquity": -0.49716, "grossProfits": -127430000, "freeCashflow": -80191128, "operatingCashflow": -133640000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "KYTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Kyverna Therapeutics, Inc.", "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.24, "epsForward": -3.93, "epsCurrentYear": -3.6514, "priceEpsCurrentYear": -1.1036863, "fiftyDayAverageChange": 1.2771003, "fiftyDayAverageChangePercent": 0.4639109, "twoHundredDayAverageChange": 0.5611503, "twoHundredDayAverageChangePercent": 0.1617684, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-02-08", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1752276480, "regularMarketTime": 1752264001, "exchange": "NMS", "messageBoardId": "finmb_650816865", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 12.8852, "regularMarketPrice": 4.03, "marketState": "CLOSED", "shortName": "Kyverna Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1707489000000, "postMarketChangePercent": -0.744422, "postMarketPrice": 4.0, "postMarketChange": -0.03000021, "regularMarketChange": 0.46, "regularMarketDayRange": "3.43 - 4.06", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 445850, "fiftyTwoWeekLowChange": 2.2500002, "fiftyTwoWeekLowChangePercent": 1.2640451, "fiftyTwoWeekRange": "1.78 - 11.4", "fiftyTwoWeekHighChange": -7.3699994, "fiftyTwoWeekHighChangePercent": -0.64649117, "fiftyTwoWeekChangePercent": -59.334003, "earningsTimestamp": 1747166523, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1755547200, "displayName": "Kyverna Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-12"}]